

Title (en)  
INDOLE DERIVATIVE, AND PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF

Title (de)  
INDOLDERIVAT UND PHARMAZEUTISCH AKZEPTABLES SALZ DARAUS

Title (fr)  
DÉRIVÉ D'INDOLE, ET SEL DE QUALITÉ PHARMACOLOGIQUE DE CELUI-CI

Publication  
**EP 2669271 A4 20140813 (EN)**

Application  
**EP 12739597 A 20120124**

Priority  
• JP 2011012956 A 20110125  
• JP 2012051401 W 20120124

Abstract (en)  
[origin: EP2669271A1] The present invention provides a compound represented by the general formula (I) of the present invention, which has EP 1 receptor antagonism: [wherein A represents a pyridine ring, a furan ring, or the like; Y 1 represents a C 1-6 alkylene group; Y 2 represents a single bond or the like; R 1 represents -C(=O)-NH-SO 2 -R 6, an acidic 5-membered hetero ring group, or the like; R 2 represents an optionally substituted phenyl group, an optionally substituted 5-membered aromatic heterocyclic group, or the like; R 3 represents a halogen atom, a C 1-6 alkoxy group, or the like; R 4 represents a hydrogen atom, a halogen atom, or the like; R 5 represents a hydrogen atom or the like; and R 6 represents a C 1-6 alkyl group or the like], and a pharmaceutically acceptable salt thereof. Furthermore, the compound (I) of the present invention can be used as an agent for treating or preventing LUTS, in particular, various symptoms of OABs.

IPC 8 full level  
**C07D 209/08** (2006.01); **A61K 31/404** (2006.01); **A61K 31/4439** (2006.01); **A61K 31/444** (2006.01); **A61K 45/00** (2006.01); **A61P 13/02** (2006.01); **A61P 13/10** (2006.01); **A61P 43/00** (2006.01); **C07D 401/06** (2006.01); **C07D 401/14** (2006.01); **C07D 405/06** (2006.01); **C07D 405/14** (2006.01); **C07D 409/14** (2006.01); **C07D 413/14** (2006.01); **C07D 417/14** (2006.01)

CPC (source: EP US)  
**A61K 31/40** (2013.01 - US); **A61K 31/4025** (2013.01 - US); **A61K 31/404** (2013.01 - EP US); **A61K 31/443** (2013.01 - EP US); **A61K 31/4439** (2013.01 - EP US); **A61K 31/444** (2013.01 - EP US); **A61K 45/06** (2013.01 - EP US); **A61P 13/02** (2017.12 - EP); **A61P 13/10** (2017.12 - EP); **A61P 43/00** (2017.12 - EP); **C07D 209/08** (2013.01 - EP US); **C07D 401/06** (2013.01 - EP US); **C07D 401/14** (2013.01 - EP US); **C07D 405/06** (2013.01 - EP US); **C07D 405/14** (2013.01 - EP US); **C07D 409/14** (2013.01 - EP US); **C07D 413/14** (2013.01 - EP US); **C07D 417/14** (2013.01 - EP US)

C-Set (source: EP US)  
EP  
1. **A61K 31/404 + A61K 2300/00**  
2. **A61K 31/4439 + A61K 2300/00**  
3. **A61K 31/444 + A61K 2300/00**  
4. **A61K 31/443 + A61K 2300/00**  
US  
**A61K 31/443 + A61K 2300/00**

Citation (search report)  
• [A] WO 0232422 A2 20020425 - PFIZER PHARMA [JP], et al  
• See references of WO 2012102254A1

Cited by  
CN103641762A; EP3517524A1

Designated contracting state (EPC)  
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)  
**EP 2669271 A1 20131204; EP 2669271 A4 20140813**; CA 2825134 A1 20120802; JP WO2012102254 A1 20140630; US 2014018335 A1 20140116; US 8796247 B2 20140805; WO 2012102254 A1 20120802

DOCDB simple family (application)  
**EP 12739597 A 20120124**; CA 2825134 A 20120124; JP 2012051401 W 20120124; JP 2012554793 A 20120124; US 201213980599 A 20120124